

August 4, 2026

Listing Department

Code: 531 335

BSE LIMITED

P. J. Towers, Dalal Street,

Mumbai-400 001

Listing Department

Code: ZYDUSWELL

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, C/1, Block G,

Bandra Kurla Complex,

Bandra (E),

Mumbai-400 051

Sub: **Outcome of Board Meeting**

Ref.: **Unaudited financial results for the quarter ended on June 30, 2026, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Dear Sir / Madam,

The Board of Directors at their meeting held today i.e. August 4, 2026, based on the recommendations of the Audit Committee, approved the unaudited financial results for the quarter ended on June 30, 2026.

In this regard, please find enclosed the following:

1. the unaudited financial results (standalone and consolidated) for the quarter ended on June 30, 2026, reviewed by the Audit Committee and taken on record by the Board of Directors, today i.e. August 4, 2026 pursuant to regulation 33 of the Listing Regulations.
2. the Limited Review Reports of Mukesh M. Shah & Co., Chartered Accountants and the Statutory Auditors of the Company certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026 pursuant to regulation 33 of the Listing Regulations.

Zydus Wellness Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481. Phone : +91-79-71800000, +91-79-48040000
Website : www.zyduswellness.com CIN : L15201GJ1994PLC023490



The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed until Thursday, August 6, 2026, and shall re-open for trading on and from Friday, August 7, 2026 for all the Directors and Designated Persons of the Company.

The Board meeting commenced at 11:30 a.m. and concluded at 12:15 p.m.

Please find the same in order.

Thanking you,

Yours faithfully,

For, **ZYDUS WELLNESS LIMITED**

NANDISH P. JOSHI
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: As above



INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To,
The Board of Directors,
Zydus Wellness Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zydus Wellness Limited** ['the Company'], for the quarter ended on June 30, 2026 ['the Statement'] attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("the Listing Regulations").
2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad
Date: August 4, 2026

UDIN: **260301900TPEYY2414**



For Mukesh M. Shah & Co
Chartered Accountants
Firm Regn. No. 106625W

Mukesh M. Shah
Partner
Membership No. 030190

**Zydus Wellness Limited**

Registered office : Zydus Corporate Park, Scheme No. 63, Survey No. 536 Khoraj (Gandhinagar), Near Vaishnodevi Circle,
Sarkhej-Gandhinagar Highway, Ahmedabad 382 481.

Tel. No. (+91-79) 4804 0000 Website: www.zyduswellness.com, CIN: L15201GJ1994PLC023490

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2026

Sr. No.	Particulars	₹ in Million			
		Quarter Ended		Year Ended	
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		[Unaudited]	[Unaudited] Refer Note 7	[Unaudited]	[Audited]
1	Income				
a	Revenue from operations				
i	Sales	1,353	1,114	1,303	5,284
ii	Other operating income	177	212	106	537
	Total Revenue from operations	1,530	1,326	1,409	5,821
b	Other income	49	48	7	119
	Total Income	1,579	1,374	1,416	5,940
2	Expenses				
a	Cost of materials consumed	1,021	831	840	3,583
b	Purchases of Stock-in-Trade	24	-	-	-
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	3	20	(28)	59
d	Employee benefits expense	153	143	174	568
e	Finance costs	30	31	23	110
f	Depreciation and amortisation expense	63	63	60	250
g	Other expenses	211	171	269	825
h	Net gain on foreign currency transactions	-	(37)	(1)	(55)
	Total Expenses	1,505	1,222	1,337	5,340
3	Profit before exceptional items and tax [1-2]	74	152	79	600
4	Exceptional items [Refer Note 5]	-	-	-	112
5	Profit before tax [3-4]	74	152	79	488
6	Tax expense				
a	Current tax	2	1	8	40
b	Deferred tax	17	18	25	72
	Total tax expense	19	19	33	112
7	Net Profit [5-6]	55	133	46	376
8	Other Comprehensive Income [OCI]				
a	Items that will not be reclassified to profit or loss				
	Re-measurement loss on cost employment defined benefit plan	-	1	(2)	(4)
	Income tax effect on above items	-	-	-	1
	Total Other Comprehensive Income [net of tax]	-	1	(2)	(3)
9	Total Comprehensive Income [7+8]	55	134	44	373
	Paid-up equity share capital [Face Value ₹ 2/- each]	636	636	636	636
	Reserve excluding Revaluation Reserve [i.e. Other equity]				39,690
	Earnings per share [not annualised for the quarter] [Refer Note 4]				
a	Basic [₹]	0.17	0.42	0.14	1.18
b	Diluted [₹]	0.17	0.42	0.14	1.18

Notes :

- The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 4, 2026.
- The above financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- The Company operates in one segment, namely "Consumer Products".
- The Board of directors at their meeting held on May 19, 2025 had approved the split / sub-division of equity shares from face value of ₹ 10/- each to ₹ 2/- each, fully paid-up. The same was effected on September 19, 2025.
- Exceptional items comprise:

Sr. No.	Particulars	₹ in Million			
		Quarter Ended		Year Ended	
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		[Unaudited]	[Unaudited] Refer Note 7	[Unaudited]	[Audited]
i.	Expenses related to liquidation of Naturell (India) Private Limited [NIPL] with the Company on a going concern basis [Refer Note-6]	-	-	-	97
ii.	One time impact of New Labour Codes	-	-	-	15
	Total	-	-	-	112

- Pursuant to the voluntary liquidation process, as approved in extra ordinary general meeting of NIPL on July 1, 2025, effective from September 20, 2025, the Liquidator of NIPL has distributed the Business Undertaking of NIPL on a going concern basis with the Company. The entire business operations of NIPL have been consolidated with the Company with effect from September 20, 2025. In view of the requirements of Appendix C to Ind AS 103 "Business Combination" preceding period figures have been restated from the date of acquisition of NIPL by the Company (i.e. December 02, 2024).
- The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and for the period up to the end of the third quarter of relevant financial year.
- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.

By Order of the Board,
For Zydus Wellness Limited,

Dr. Sharvil P. Patel
Chairman

Place: Ahmedabad
Date: August 4, 2026

DIN: 00131995

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To,
The Board of Directors,
Zydus Wellness Limited

1. We have reviewed the accompanying statement of Consolidated unaudited financial results of **Zydus Wellness Limited** ['the Parent'] and its subsidiaries [the Parent and its subsidiaries together referred to as 'the Group'] for the quarter ended on June 30, 2026 ['the Statement'] attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("the Listing Regulations").
2. This statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Listing Regulations, as amended, to the extent applicable.
4. The Statement includes the financial results of the following entities:
 - a) Parent Company
 - i) Zydus Wellness Limited
 - b) Subsidiary Companies
 - i) Zydus Wellness Products Limited
 - ii) Liva Nutritions Limited
 - iii) Alidac UK Limited
 - iv) Comfort Click Softech Private Limited
 - v) Comfort Click Limited, UK
 - vi) Comfort Click Limited, Ireland
 - vii) Comfort Click LLC
 - viii) Zydus Wellness International DMCC
 - ix) Zydus Wellness (BD) Pvt Limited
 - x) Naturell Inc.
 - xi) Zydus Wellness General Trading DWC-LLC
 - xii) Zydus Wellness Trading LLC
 - xiii) Zydus Wellness (EU) Limited



5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 6 subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect [the figures reported below are before giving effect to consolidation adjustments] total income of ₹ 14,855 million for the quarter ended June 30, 2026, total net profit after tax of ₹ 1,268 million for the quarter ended June 30, 2026, total comprehensive income of ₹ 1,268 million for the quarter ended June 30, 2026, as considered in the Statement. This interim financial information has been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated financial results also include the financial information of 5 subsidiary companies included in the consolidated unaudited financial results, whose interim financial information reflects [the figures reported below are before giving effect to consolidation adjustments] total income of ₹ 231 million for the quarter ended June 30, 2026, total net Loss after tax of ₹ 28 million for the quarter ended June 30, 2026, total comprehensive income of ₹ (28) million for the quarter ended June 30, 2026, as considered in the Statement. No limited review of this financial information has been carried out by the auditors of the subsidiary; however, according to the information and explanations given to us by the Management, this interim financial results / information is not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information as certified by the management.

Place: Ahmedabad
Date: August 4, 2026

UDIN: 26030190 XRY KQL 4791



For Mukesh M. Shah & Co
Chartered Accountants
Firm Regn. No. 106625W

Mukesh M. Shah
Partner
Membership No. 030190

Zydus Wellness Limited

Registered office : Zydus Corporate Park, Scheme No. 63, Survey No. 536 Khoraj (Gandhinagar), Near Vaishnodevi Circle,

Sarkhej-Gandhinagar Highway, Ahmedabad 382 481.

Tel. No. (+91-79) 4804 0000 Website: www.zyduswellness.com, CIN: L15201GJ1994PLC023490

Statement of Consolidated Unaudited Financial Results for the Quarter ended June 30, 2026

Sr. No.	Particulars	₹ in Million			
		Quarter Ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		[Unaudited]	[Unaudited] Refer Note 11	[Unaudited]	[Audited]
1	Income				
a	Revenue from operations				
i	Sales	14,299	14,761	8,577	39,400
ii	Other operating income	71	86	32	210
	Total Revenue from operations	14,370	14,847	8,609	39,610
b	Other income	38	12	30	64
	Total Income	14,408	14,859	8,639	39,674
2	Expenses				
a	Cost of materials consumed	3,076	3,844	2,672	12,123
b	Purchases of stock-in-trade	1,426	1,923	512	4,164
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	432	(570)	694	(618)
d	Employee benefits expense	968	1,046	682	3,130
e	Finance costs	263	387	25	981
f	Depreciation and amortisation expense	571	553	108	1,467
g	Advertisement and promotion expense	2,612	2,411	1,325	6,459
h	Other expenses	3,435	3,540	1,171	9,329
i	Net [gain]/ loss on foreign currency transactions	4	(48)	(3)	(74)
	Total Expenses	12,787	13,086	7,186	36,961
3	Profit before exceptional items and tax [1-2]	1,621	1,773	1,453	2,713
4	Exceptional items [Refer Note 5]	-	-	-	408
5	Profit before tax [3-4]	1,621	1,773	1,453	2,305
5	Tax expense				
a	Current tax	401	117	8	306
b	Deferred tax [Refer Note 6]	31	36	166	27
	Total tax expense	432	153	174	333
7	Net Profit [5-6]	1,189	1,620	1,279	1,972
8	Other Comprehensive Income [OCI]				
a	Items that will not be reclassified to profit or loss				
	Re-measurement loss on cost employment defined benefit plan	-	1	(2)	(5)
	Income tax effect on above items	-	-	-	1
	Total	-	1	(2)	(4)
b	Items that will be reclassified to profit or loss				
	Exchange differences on translation of financial statement of foreign operations	(110)	(23)	2	(42)
	Total	(110)	(23)	2	(42)
	Total Other Comprehensive Income [net of tax]	(110)	(22)	-	(46)
9	Total Comprehensive Income [7+8]	1,079	1,598	1,279	1,926
10	Paid-up equity share capital [Face Value ₹ 2/- each]	636	636	636	636
11	Reserve excluding Revaluation Reserve [i.e. Other equity]				57,624
12	Earnings per share [not annualised for the quarter] [Refer Note 10]				
a	Basic [₹]	3.74	5.09	4.02	6.20
b	Diluted [₹]	3.74	5.09	4.02	6.20

Notes :

- The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on August 4, 2026.
- The above financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- The Group operates in one segment, namely "Consumer Products".
- Due to seasonality of some of the Group's products, Group's Revenues and Group's Profits are skewed in favour of the first and last quarters of the financial year. Hence the performance of these quarters is not representative and cannot be generalised for other quarters.
- Exceptional items comprise:

Sr No	Particulars	₹ in Million			
		Quarter Ended			
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		[Unaudited]	[Unaudited] Refer Note 11	[Unaudited]	[Audited]
i.	Expenses related to liquidation of Naturell (India) Private Limited [NIPL], a subsidiary of the Company, on a going concern basis [Refer Note-8]	-	-	-	97
ii.	Expenses related to acquisition of Comfort Click Limited [CCL] [Refer Note-9]	-	-	-	245
iii.	One time impact of New Labour Codes	-	-	-	66
	Total	-	-	-	408

6. Financial results for the quarter ended June 30, 2026, March 31, 2026, and June 30, 2025, and for the year ended March 31, 2026, include a net reversal of Minimum Alternate Tax (MAT) credit entitlement amounting to Nil, ₹218 million, ₹146 million, and ₹354 million respectively.
7. As on June 30, 2026 the company has following subsidiaries:
- Zydus Wellness Products Limited
 - Zydus Wellness (BD) Pvt Limited
 - Zydus Wellness International DMCC
 - Liva Nutritions Limited
 - Naturell Inc
 - Alidac UK Limited
 - Comfort Click Limited, UK
 - Comfort Click Softech Private Limited
 - Comfort Click Limited, Ireland
 - Comfort Click LLC
 - Zydus Wellness General Trading DWC-LLC
 - Zydus Wellness Trading L.L.C.
 - Zydus Wellness (EU) Limited
8. On July 1, 2025 a special resolution was passed in the extra ordinary general meeting of NIPL to approve the voluntarily liquidation of NIPL on a going concern basis. Pursuant to the same, the Liquidator of NIPL, has distributed the entire business undertaking of NIPL on a going concern basis to the Company on and with effect from September 20, 2025. The entire business operations of NIPL stands consolidated with the Company with effect from September 20, 2025. The Company has given effect of the liquidation as per the requirements of Appendix C to Ind AS 103 "Business Combination".
9. Pursuant to the Share Purchase Agreement ["SPA"] entered into by Alidac UK Limited [Alidac], a wholly owned subsidiary of the Company, on August 29, 2025, to acquire Comfort Click Limited [CCL], Alidac has successfully completed the acquisition of CCL on August 29, 2025. Alidac acquired 100% outstanding ordinary shares of Class A and Class B, 71.43% of non-controlling ordinary shares of Class C and 66.67% of non-controlling ordinary shares of Class D of CCL. The cost of acquisition is GBP 239 million, along with a profit-ticker payment of GBP 2.64 million, in accordance with the terms of SPA. The results include the operations of CCL effective from August 29, 2025, with provisional purchase price allocation [PPA] figures. The PPA figures will be finalized within the measurement period, as provided by Ind AS 103 "Business Combination".
10. The Board of directors at their meeting held on May 19, 2025 had approved the split / sub-division of equity shares from face value of ₹ 10/- each to ₹ 2/- each, fully paid-up. The same was effected on September 19, 2025.
11. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full financial year and for the period up to the end of the third quarter of relevant financial year.
12. Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the figures of the current reporting period.
13. The detailed standalone results are available on the Company's website: www.zyduswellness.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. The summarised standalone financial results of the Company are as below:

Sr. No	Particulars	₹ in Million			
		Quarter Ended			
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		[Unaudited]	[Unaudited] Refer Note 11	[Unaudited]	[Audited]
i.	Revenue from operations	1,530	1,326	1,409	5,821
ii.	Profit before exceptional items and tax	74	152	79	600
iii.	Profit after tax	55	133	46	376
iv.	Other Comprehensive Income	-	1	(2)	(3)
v.	Total Comprehensive Income	55	134	44	373

By Order of the Board,
For Zydus Wellness Limited,



Place: Ahmedabad
Date: August 4, 2026

Dr. Sharvil P. Patel
Chairman
DIN: 00131995